Find a Research Study

This is a randomized, double-blind, placebo-controlled study that will evaluate the potential of tildacerfont to reduce GC burden in adult subjects with classic CAH who have LLD ≤ A4 ≤ 2.5x ULN and are on supraphysiologic doses of GC therapy (≥30 mg/day and ≤60 mg/day HCe). This will be the first study of tildacerfont to evaluate GC dose reduction. In addition, this study will characterize clinical outcomes after up to 76 weeks of treatment with tildacerfont. An optional Open-Label Extension Period will provide an open-label treatment with tildacerfont at 200 mg QD for up to 240 weeks.

Study early development in infants who have an older sibling with autism.

Understand the experiences of patients and parents in treatment decision making for children with Neuromuscular Scoliosis (NMS).

To better understand the effects of nutrition in early pregnancy on infant growth and development.

The primary aim of this registry will be to identify genes and/or biologic and environmental factors that either cause these tumors or increase one's risk for developing them. Ultimately, research using this registry may result in improved diagnosis, more effective treatments and possibly prevention.

The objective of this study is to better understand the effects of chronic diseases, such as congenital heart disease, on blood vessel function and on blood characteristics.